

# The association between various diagnostic measurements and lung function

<b>Submission date</b> 14/02/2020	<b>Recruitment status</b> Recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 08/06/2020	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 04/04/2025	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Background and study aims

The main function of lungs is gas exchange through gas transport. Due to the complexity of the lung structure, gas transport can only be optimized to a certain extent and is easily affected by changes in the small airways.

The overall aim of this study is to prospectively associate various pulmonary function tests with clinical, laboratory, histological and radiological characteristics.

Who can participate?

People aged 18 years or above.

What does the study involve?

Participants will undergo several lung function tests during a single visit.

What are the possible benefits and risks of participating?

None.

Where is the study run from?

University Hospital Basel, Clinic for Respiratory Medicine and Pulmonary Cell Research (Switzerland)

When is the study starting and how long is it expected to run for?

April 2019 to April 2028

Who is funding the study?

University Hospital Basel (Switzerland)

Who is the main contact?

Prof. Daiana Stolz  
daiana.stolz@usb.ch

## Contact information

**Type(s)**

Scientific

**Contact name**

Prof Daiana Stolz

**ORCID ID**

<http://orcid.org/0000-0003-0099-882X>

**Contact details**

University Hospital of Basel  
Clinic for Respiratory Medicine and Pulmonary Cell Research  
Petersgraben 4  
Basel  
Switzerland  
4031  
+41 612654422  
[daiana.stolz@usb.ch](mailto:daiana.stolz@usb.ch)

**Type(s)**

Scientific

**Contact name**

Dr Vivian Suarez Domenech

**Contact details**

Universitätsspital Basel  
Pneumologie  
Petersgraben 4  
Basel  
Switzerland  
4031  
+41 61 328 69 17  
[vivian.suarezdomenech@usb.ch](mailto:vivian.suarezdomenech@usb.ch)

**Additional identifiers****EudraCT/CTIS number**

Nil known

**IRAS number****ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

PFT\_Prosp\_Amendment 01

**Study information**

**Scientific Title**

Pulmonary function test association with clinical, laboratory, histological and radiological characteristics – a prospective study

**Acronym**

N2

**Study objectives**

The overall aim of this study is to prospectively associate various pulmonary function tests with clinical, laboratory, histological and radiological characteristics.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 22/02/2019, EKNZ (Ethics Committee Northern and Central Switzerland, Hebelstrasse 53, Basel 4056, Switzerland; +41 612681350; eknz@bs.ch), ref : 2018-0286, Amendment approved 27/11/2019

**Study design**

Observational longitudinal study

**Primary study design**

Observational

**Secondary study design**

Longitudinal study

**Study setting(s)**

Hospital

**Study type(s)**

Screening

**Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

**Health condition(s) or problem(s) studied**

Respiratory diseases

**Interventions**

Non-invasive measurements specific to the project and performed in all participants, include:

N2 washout (single and multiple breath):

Single breath - the measurements are carried out with the patient sitting upright and breathing normally. The test subjects breathe through a mouthpiece with a nose clamp that is attached to the measuring device. A bacteria filter is installed upstream of the measuring device. The filter, mouthpiece and nose clip are replaced after each patient. The measurement device is based on an ultrasonic flow head, the Exhalyzer® (Eco Medics AG, Dürnten, Switzerland), connected to a bypass element that provides constant air intake. The gas used as part of the study (100% O<sub>2</sub>,

DTG) is supplied to the patient via this bypass element. During the measurement procedure, the accurate recording of the flow volume curve and the gas signals (O<sub>2</sub>, CO<sub>2</sub> and the derived N<sub>2</sub>, molar mass signal) enable good online monitoring of the measurement quality. Any changes to the patient's breathing pattern, hyperventilation or leaks are identified immediately and the measurement procedure is terminated.

Multiple breath - for N<sub>2</sub> MBW, the supply of 100% O<sub>2</sub> flushes out the nitrogen in the lungs. The test ends when < 2% end-expiratory N<sub>2</sub> (1/40 of the starting concentration) is reached over three consecutive breaths. For the evaluation, all signals are aligned in terms of time, and the respiratory flows and derived breathing volumes are corrected for body temperature, ambient pressure and humidity. To calculate the functional residual capacity (FRC), the ratio (net volume of expired tracer gas) / [(end-expiratory N<sub>2</sub> concentration at start of washout measurement) – (end-expiratory N<sub>2</sub> concentration at end of the washout measurement)] is calculated. Over the course of the three requisite measurements per patient, the FRC must not deviate by more than 20%; otherwise, the measurement must be rejected. The LCI is calculated via FRC as the ratio of the cumulative expired volume.

Forced oscillation technique (FOT) - the sound waves, generated with the help of a loudspeaker are transmitted into the lungs of the subject. These sound waves, which are essentially pressure waves, cause changes in the pressure and this change in pressure drives changes in airflow. By measuring the magnitude of change in the pressure and flow, one can determine the mechanical properties of the lung. Waves of lower frequencies travel deep into the lungs till and into the alveoli and are reflected back while those of higher frequencies are reflected from the larger airways. Thus, the parameters calculated at different frequencies give measures of different regions in the lungs.

Aeonose – Measured data consists of an individual breath-print of volatile organic compounds. Patients breathe into the portable Aeonose for five minutes. The system learns from each data entered and is updating consistently. The device is CE-certified and therefore there is no risk in using it for our patients.

Sleepiz One – A contactless, non-invasive device that measures vital parameters while patient is at rest. It is a radar-based sensor that does not pose any risks. The electromagnetic emission is around 100 times lower than that of a typical mobile phone.

Along with the study-specific interventions, routine interventions such as body plethysmography are also performed.

## **Intervention Type**

Other

## **Primary outcome measure**

Measured at a single time point:

1. LCI measured using the multiple-breath nitrogen washout (N<sub>2</sub>-MBW)
2. Phase III slope (S<sub>III</sub>) measured using the single-breath nitrogen washout (N<sub>2</sub>-SBW) and single-breath double tracer gas washout (DTG-SBW)

## **Secondary outcome measures**

Measured at a single time point:

1. Scond, Sacin, area under the curve of DTG-SBW measured using the multiple-breath nitrogen washout (N<sub>2</sub>-MBW)
2. Bronchoprovocation test outcomes such as PD<sub>20</sub> and PD<sub>40</sub>
3. Volatile organic compounds in the breath measured using Aeonose
4. Sleepiz One measurements (breathing, heart rate, movement during sleep)
5. Known clinical, laboratory, histological and radiological characteristics measured using patient records

**Overall study start date**

01/04/2019

**Completion date**

30/04/2028

## Eligibility

**Key inclusion criteria**

1. Older than 18 years
2. Capable to perform an acceptable spirometry
3. Able to answer questionnaires
4. With or without respiratory symptoms
5. With or without diagnosed respiratory disease

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

20000

**Key exclusion criteria**

Does not meet inclusion criteria

**Date of first enrolment**

01/04/2019

**Date of final enrolment**

30/04/2028

## Locations

**Countries of recruitment**

Switzerland

**Study participating centre**

**University Hospital Basel**

Clinic for Respiratory Medicine and Pulmonary Cell Research  
Petersgraben 4

Basel  
Switzerland  
4031

## Sponsor information

### Organisation

University Hospital of Basel

### Sponsor details

Clinic for Respiratory Medicine and Pulmonary Cell Research  
Petersgraben 4  
Basel  
Switzerland  
4031  
+41 612654422  
daiana.stolz@usb.ch

### Sponsor type

Hospital/treatment centre

### Website

<https://www.unispital-basel.ch/>

### ROR

<https://ror.org/04k51q396>

## Funder(s)

### Funder type

Hospital/treatment centre

### Funder Name

University Hospital Basel

## Results and Publications

### Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

### Intention to publish date

30/04/2029

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol file</a>	version v5	27/11/2019	03/07/2020	No	No
<a href="#">Results article</a>		03/04/2025	04/04/2025	Yes	No